CascinuS.: Tumori gastrointestinali.Progressi nella terapia. Il Pensiero Scientifico Editore, pp 1–103, 2000.
2.
SobreroA.F., HerrmannH., RischinD., ZalcbergJ.: Current controversies in cancer: does biomodulation of 5-fluorouracil improve results?Eur J Cancer, 35: 186–194, 1999.
3.
Liver Infusion Meta-analysis Group:Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies.J Natl Cancer Inst, 89: 497–505, 1997.
4.
RougierP., SahmoudT., NittiD.: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomized trial.Lancet, 351: 1677–1681, 1998.
5.
LabiancaR., BoffiL., MarsoniS.: A randomized trial of intraportal (IP) versus systemic (SY) versus IP+SY adjuvant chemotherapy in patients with resected Dukes B-C colon carcinoma.Proceedings ASCO,18: 264a, 1999.
6.
MamounasE.P., WieandS., WolmarkN.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04).J Clin Oncol, 17: 1349–1355, 1999.
7.
IMPACT B2 Investigators:Effect of adjuvant fluorouracil and folinic acid in B2 colon cancer.J Clin Oncol,17: 1356–1363, 1999.
8.
RiethmullerG., HolzE., SchlimokG.: Monoclonal antibody therapy for resected Dukes C colorectal cancer.Seven-year outcome of a multicenter randomized trial. J Clin Oncol, 16: 1788–1794, 1998.
9.
VermorkenJ.B., ClaessenA.M.E., van TinterenH.: Active specific immunotherapy for stage II and III human colon cancer: a randomized trial.Lancet, 353: 345–350, 1999.
10.
HarringtonD.P.: The tea leaves of small trials (Editorial).J Clin Oncol, 17: 1336–1338, 1999.
11.
ElsalehH., JosephD.J., JacopettaB.: Microsatellite instability is a strong molecular predictive marker for sensitivity to adjuvant chemotherapy in Dukes C colorectal carcinoma.Proceedings ASCO,19: 238a, 2000.
12.
Le VoyerT.R., SigurdsonE.R., HanlonA.L.: Colon cancer survival is associated with increasing number of lymph nodes removed. A secondary analysis of INT-0089.Proceedings ASCO,19: 239a, 2000.
13.
SargentD., GoldbergR., MacDonaldJ.: Adjuvant chemotherapy for colon cancer is beneficial without significantly increasd toxicity in elderly patients: results from a 3351 pt meta-analysis.Proceedings ASCO,19: 241a, 2000.
14.
SainiA., CunninghamD., NormanA.R.: Multicentre randomized trial of protracted venous infusion (PVI) 5FU compared to 5FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer.Proceedings ASCO,19: 240a, 2000.
15.
PoplinE., BenedettiJ., EstesN.: Phase III randomized trial of bolus 5FU/leucovorin/levamisole versus 5FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153).Proceedings ASCO,19: 240a, 2000.
16.
SalzL.B., DouillardJ., PirottaN.: Combined analysis of two phase III randomized trials comparing irinotecan, fluorouracil, leucovorin vs fluorouracil alone as first-line therapy of previously untreated metastatic colorectal cancer.Proceedings ASCO,19: 242a, 2000.
17.
SobreroA., KerrD., GlimeliusB.: New directions in the treatment of colorectal cancer: a look to the future.Eur J Cancer, 36: 559–566, 2000.
